CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a poor prognosis and limited treatment options. Considering that alterations of the CDK4/6-cyclin D-Rb pathway occur frequently in HCC, we tested the efficacy of two CDK4/6 inhibitors, abemaciclib and ribociclib, in combin...

全面介紹

書目詳細資料

發表在:	Frontiers in Oncology
Main Authors:	Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni, Maricla Galetti, Rita Terenziani, Kamal Eltayeb, Francesco Volta, Silvia Zoppi, Patrizia Bertolini, Gabriele Missale, Roberta Alfieri, Pier Giorgio Petronini
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2022-07-01
主題:	hepatocarcinoma (HCC) CDK4/6 inhibition abemaciclib lenvatinib senescence
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2022.942341/full